Solasia Pharma K.K Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 5/6

Solasia Pharma K.K hat ein Gesamteigenkapital von ¥2.2B und eine Gesamtverschuldung von ¥0.0, was einen Verschuldungsgrad von 0% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen ¥2.4B bzw. ¥166.0M.

Wichtige Informationen

Verhältnis von Schulden zu Eigenkapital

JP¥0

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	JP¥1.04b
Eigenkapital	JP¥2.21b
Gesamtverbindlichkeiten	JP¥166.00m
Gesamtvermögen	JP¥2.38b

Jüngste Berichte zur Finanzlage

Keine Aktualisierungen

Recent updates

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: 4597Die kurzfristigen Aktiva des Unternehmens (¥1.3B) übersteigen seine kurzfristigen Passiva (¥150.0M).

Langfristige Verbindlichkeiten: 4597Die kurzfristigen Vermögenswerte des Unternehmens (¥1.3B) übersteigen seine langfristigen Verbindlichkeiten (¥16.0M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: 4597 ist schuldenfrei.

Schulden abbauen: 4597 hatte vor 5 Jahren keine Schulden.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: 4597 auf der Grundlage seines derzeitigen freier Cashflows über eine ausreichende Liquiditätsreserve für mehr als ein Jahr verfügt.

Vorhersage Cash Runway: Unzureichende Daten, um festzustellen, ob 4597 über genügend Cash Runway verfügt, wenn sein freier Cashflow auf der Grundlage historischer Raten weiter wächst oder schrumpft.

Solasia Pharma K.K Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Recent updates

New major risk - Revenue size

Second quarter 2024 earnings released: JP¥1.58 loss per share (vs JP¥1.17 loss in 2Q 2023)

First quarter 2024 earnings released: JP¥1.78 loss per share (vs JP¥1.44 loss in 1Q 2023)

Solasia Pharma K.K. Provides Consolidated Earnings Forecasts for the Fiscal Year Ending December 31, 2024

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

New minor risk - Profitability

Solasia Pharma K.K. announced that it has received KRW 504.33 million in funding from Macquarie Group Limited

Consensus EPS estimates fall by 36%, revenue upgraded

Forecast breakeven date pushed back to 2026

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Solasia Pharma K.K. announced that it expects to receive KRW 504.33 million in funding from Macquarie Group Limited

Solasia Pharma K.K., Annual General Meeting, Mar 22, 2024

New minor risk - Shareholder dilution

Consensus revenue estimates fall by 66%

New major risk - Financial position

Solasia Pharma K.K. Revises Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023

Solasia Pharma K.K. to Report Q2, 2024 Results on Aug 14, 2024

New major risk - Share price stability

Third quarter 2023 earnings released: JP¥1.97 loss per share (vs JP¥4.95 loss in 3Q 2022)

Second quarter 2023 earnings released: JP¥1.17 loss per share (vs JP¥4.38 loss in 2Q 2022)

First quarter 2023 earnings released: JP¥1.44 loss per share (vs JP¥4.61 loss in 1Q 2022)

Insufficient new directors

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Solasia Pharma K.K., Annual General Meeting, Mar 23, 2023

Solasia Pharma K.K. to Report Fiscal Year 2022 Results on Feb 14, 2023

Solasia Pharma K.K. Revises Consolidated Financial Guidance for the Fiscal Year Ending December 31, 2022

An unknown buyer acquired unknown minority stake in Solasia Pharma K.K. (TSE:4597) from ITOCHU Corporation (TSE:8001).

Third quarter 2022 earnings released: JP¥4.95 loss per share (vs JP¥5.46 loss in 3Q 2021)

Solasia Pharma K.K. Revises Consolidated Financial Guidance for the Fiscal Year Ending December 31, 2022

Now 21% undervalued after recent price drop

Now 22% undervalued after recent price drop

Now 21% undervalued after recent price drop

Solasia Announces Summary of SP-04 PledOx Development Status

Solasia Announces Summary of SP-04 PledOx Development Status

Solasia Announces Launch of Darvias in Japan

Second quarter 2022 earnings released: JP¥4.38 loss per share (vs JP¥5.67 loss in 2Q 2021)

Solasia Pharma K.K. Provides Consolidated Financial Guidance for the Fiscal Year Ending December 31, 2022

Solasia Pharma K.K. Announces Topline Data from Phase III AGENT Study of SP-05(arfolitixorin)

Solasia Pharma K.K. announced that it has received ¥1.02 billion in funding from Nippon Kayaku Co., Ltd.

Solasia Pharma K.K. announced that it has received ¥1.02 billion in funding from Nippon Kayaku Co., Ltd.

Solasia Pharma K.K. (TSE : 4597) acquired Episil oral liquid business from Camurus AB (publ) (OM : CAMX).

Solasia Pharma K.K. announced that it expects to receive ¥1.02 billion in funding from Nippon Kayaku Co., Ltd.

Solasia Pharma K.K. Announces an Organoarsenic Drug "Darvias® Injection 135Mg" (Sp-02, Hereinafter Darvias®) Has Been Approved for Relapsed or Refractory Peripheral T-Cell Lymphoma by the Ministry of Health, Labor and Welfare

First quarter 2022 earnings released: JP¥4.61 loss per share (vs JP¥5.22 loss in 1Q 2021)

Solasia Pharma K.K. announced that it has received ¥3.94289 billion in funding from Macquarie Group Limited

Solasia Pharma K.K. announced that it has received ¥3.94289 billion in funding from Macquarie Group Limited

Solasia Pharma K.K. to Report Q3, 2022 Results on Nov 11, 2022

Solasia Pharma K.K. announced that it expects to receive ¥3.44289 billion in funding from Macquarie Group Limited

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Solasia Pharma K.K. Provides Consolidated Financial Guidance for the Fiscal Year Ending December 31, 2022

Solasia Pharma K.K., Annual General Meeting, Feb 24, 2022

Third quarter 2021 earnings released: JP¥5.46 loss per share (vs JP¥5.71 loss in 3Q 2020)

Second quarter 2021 earnings released: JP¥5.67 loss per share (vs JP¥6.36 loss in 2Q 2020)

Solasia Pharma K.K. Announces Submission of New Drug Application for Anti-cancer Drug DARINAPARSIN for Peripheral T-Cell Lymphoma in Japan

First quarter 2021 earnings released: JP¥5.22 loss per share (vs JP¥4.54 loss in 1Q 2020)

Full year 2020 earnings released: JP¥35.16 loss per share (vs JP¥17.75 loss in FY 2019)

Solasia Pharma K.K. to Report Q1, 2021 Results on May 12, 2021

New 90-day high: JP¥158

Full year 2020 earnings released: JP¥35.16 loss per share (vs JP¥17.75 loss in FY 2019)

Solasia Pharma K.K., Annual General Meeting, Mar 29, 2021

Solasia Pharma K.K. to Report Fiscal Year 2020 Results on Feb 16, 2021

Solasia Pharma K.K. Revises Consolidated Earnings Guidance for the Year Ending December 31, 2020

New 90-day low: JP¥123

Solasia Pharma K.K. announced that it expects to receive ¥13.44 million in funding from Macquarie Group Limited

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Liquiditätsreserve-Analyse

Entdecken Sie finanziell stabile Unternehmen